FLORENCE, Italy and NEW YORK, Nov. 26, 2024 /CNW/ -- The Menarini Group ("Menarini"), a leading international pharmaceutical and diagnostics company, and Stemline Therapeutics, Inc. ("Stemline"), a wholly-owned subsidiary of the Menarini Group, focused on bringing transformational oncology treatments to cancer patients, will present new and expanded data on ORSERDU® (elacestrant) at the upcoming 2024 San Antonio Breast Cancer Symposium (SABCS), December 10-13, 2024. Of note, the company will bring real-world progression-free survival (rwPFS) results of ORSERDU in adult patients with ER+/HER2-, advanced or metastatic breast cancer (mBC). Additionally, the company will present updated efficacy results of elacestrant plus abemaciclib, along with a pooled safety analysis from phase 1b/2 of both the ELECTRA and ELEVATE trials.
Read more at newswire.caMenarini Group Presents New and Expanded Data at the 2024 San Antonio Breast Cancer Symposium Reinforcing the Role of ORSERDU® (Elacestrant) for Patients with ER+, HER2- Advanced or Metastatic Breast Cancer (mBC)
Newswire.ca - Press Release
All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here
/amazon%20holiday%20delivery%20boxes%20by%20Cineberg%20via%20iStock.jpg)
/Semiconductor%20Chip%20by%20Gorodenkoff%20via%20Shutterstock.jpg)
/NVIDIA%20Corp%20logo%20on%20phone%20and%20AI%20chip-by%20Below%20the%20Sky%20via%20Shutterstock.jpg)
/NVIDIA%20Corp%20video%20chip-by%20Antonio%20Bordunovi%20via%20iStock.jpg)
